A CRUK first-in-human phase I trial of LY3143921, a novel CDC7 inhibitor, in patients with advanced solid tumors.

被引：0

作者：

Gallagher, Peter F.

Naylor, Gregory

Bashir, Saira

Yan, Xiangfei

Burke, David

Plummer, Elizabeth Ruth

Evans, T. R. Jeffry

Coyle, Victoria M.

Clive, Sally

McGuigan, Lesley

Heinzmann, Kathrin

Halbert, Gavin

Veal, Gareth

Tiplady, Eleanor

Barnett, Shelby

Yalla, Krishna

Brook, Sue

Dobbs, Nicola

Wilson, Richard H.

机构：

[1] Queens Univ Belfast, Belfast, Antrim, North Ireland

[2] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[3] Newcastle Univ, Ctr Canc, Newcastle Upon Tyne, Tyne & Wear, England

[4] Western Gen Hosp, Edinburgh Canc Ctr, Edinburgh, Midlothian, Scotland

[5] Queens Univ Belfast, Belfast, Antrim, North Ireland

[6] Canc Res UK, Ctr Drug Dev, London, England

[7] Univ Strathclyde, CRUK Formulat Unit, Glasgow, Lanark, Scotland

[8] Univ Glasgow, Translat Pharmacol Lab, Glasgow, Lanark, Scotland

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3103

引用

页数：1